These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 23687298

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S, Tian J, Niu Y, Li L, Yeh S, Chang C.
    Cancer Lett; 2016 Jul 01; 376(2):377-86. PubMed ID: 27045473
    [Abstract] [Full Text] [Related]

  • 4. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
    Wen S, Niu Y, Lee SO, Yeh S, Shang Z, Gao H, Li Y, Chou F, Chang C.
    Mol Carcinog; 2016 Dec 01; 55(12):2278-2290. PubMed ID: 26894509
    [Abstract] [Full Text] [Related]

  • 5. ASC-J9® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3.
    Lin W, Luo J, Sun Y, Lin C, Li G, Niu Y, Chang C.
    Cancer Lett; 2018 Jul 01; 425():21-30. PubMed ID: 29425687
    [Abstract] [Full Text] [Related]

  • 6. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.
    Wang R, Sun Y, Li L, Niu Y, Lin W, Lin C, Antonarakis ES, Luo J, Yeh S, Chang C.
    Eur Urol; 2017 Nov 01; 72(5):835-844. PubMed ID: 28528814
    [Abstract] [Full Text] [Related]

  • 7. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
    Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ, Yeh S, Chang C.
    Neoplasia; 2012 Jan 01; 14(1):74-83. PubMed ID: 22355276
    [Abstract] [Full Text] [Related]

  • 8. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO, Fukumori T, Daizumoto K, Fukawa T, Kohzuki M, Kowada M, Kusuhara Y, Mori H, Nakatsuji H, Takahashi M, Kanayama HO.
    Anticancer Res; 2017 Jan 01; 37(1):125-134. PubMed ID: 28011482
    [Abstract] [Full Text] [Related]

  • 9. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L, Dang Q, Xie H, Yang Z, He D, Liang L, Song W, Yeh S, Chang C.
    Oncotarget; 2015 Jun 10; 6(16):14179-90. PubMed ID: 25895025
    [Abstract] [Full Text] [Related]

  • 10. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP, Huang CK, Chang YJ, Chung CY, Yamashita S, Li L, Lee SO, Yeh S, Chang C.
    Am J Pathol; 2013 Feb 10; 182(2):460-73. PubMed ID: 23219429
    [Abstract] [Full Text] [Related]

  • 11. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
    Deng G, Wang R, Sun Y, Huang CP, Yeh S, You B, Feng C, Li G, Ma S, Chang C.
    Cell Death Differ; 2021 Jul 10; 28(7):2145-2159. PubMed ID: 34127806
    [Abstract] [Full Text] [Related]

  • 12. Androgen receptor (AR) degradation enhancer ASC-J9® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth.
    Cheng MA, Chou FJ, Wang K, Yang R, Ding J, Zhang Q, Li G, Yeh S, Xu D, Chang C.
    Cancer Lett; 2018 Mar 28; 417():182-191. PubMed ID: 29203251
    [Abstract] [Full Text] [Related]

  • 13. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R, Lin W, Lin C, Li L, Sun Y, Chang C.
    Cancer Lett; 2016 Aug 28; 379(1):154-60. PubMed ID: 27233475
    [Abstract] [Full Text] [Related]

  • 14. Telomerase as an important target of androgen signaling blockade for prostate cancer treatment.
    Liu S, Qi Y, Ge Y, Duplessis T, Rowan BG, Ip C, Cheng H, Rennie PS, Horikawa I, Lustig AJ, Yu Q, Zhang H, Dong Y.
    Mol Cancer Ther; 2010 Jul 28; 9(7):2016-25. PubMed ID: 20571066
    [Abstract] [Full Text] [Related]

  • 15. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.
    Recouvreux MV, Wu JB, Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung LW, Melmed S.
    Endocrinology; 2017 Jul 01; 158(7):2255-2268. PubMed ID: 28444169
    [Abstract] [Full Text] [Related]

  • 16. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
    Dang Q, Li L, Xie H, He D, Chen J, Song W, Chang LS, Chang HC, Yeh S, Chang C.
    Mol Oncol; 2015 Aug 01; 9(7):1241-51. PubMed ID: 25817444
    [Abstract] [Full Text] [Related]

  • 17. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.
    Tian H, Chou FJ, Tian J, Zhang Y, You B, Huang CP, Yeh S, Niu Y, Chang C.
    J Exp Clin Cancer Res; 2021 Jan 04; 40(1):3. PubMed ID: 33390173
    [Abstract] [Full Text] [Related]

  • 18. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
    Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.
    Prostate; 2013 Sep 04; 73(12):1291-305. PubMed ID: 23765603
    [Abstract] [Full Text] [Related]

  • 19. Correction: Differential androgen deprivation therapies with anti-androgens Casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9® lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, Yeh SD, Fujimoto N, Yeh S, Chang C.
    J Biol Chem; 2020 Nov 13; 295(46):15796. PubMed ID: 33188084
    [No Abstract] [Full Text] [Related]

  • 20. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC.
    Mol Cancer Ther; 2017 Aug 13; 16(8):1521-1530. PubMed ID: 28500234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.